行情

HALO

HALO

奥洛兹美医疗
NASDAQ

实时行情|Nasdaq Last Sale

17.69
+1.02
+6.12%
盘后: 17.69 0 0.00% 16:00 04/08 EDT
开盘
16.80
昨收
16.67
最高
17.83
最低
16.55
成交量
172.92万
成交额
--
52周最高
22.06
52周最低
12.71
市值
24.42亿
市盈率(TTM)
-35.1341
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HALO价格均价为24.20,最高价位35.00,最低价为12.00。

EPS

HALO 新闻

更多
  • Halozyme Announces Change Of Location Of Annual Stockholders' Meeting
  • PR Newswire · 5天前
  • Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
  • Insider Monkey · 03/29 22:44
  • Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/25 16:30
  • Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?
  • Zacks · 03/19 15:30

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

HALO 简况

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
展开

微牛提供Halozyme Therapeutics, Inc.(NASDAQ-HALO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HALO股票新闻,以帮助您做出投资决策。